Product Introduction:
AxeniQ is a high-purity Botulinum Toxin Type A developed with advanced aesthetic expertise by Genése Labs in France. It is designed to deliver precision, reliability, and consistent clinical performance, making it suitable for a wide range of facial aesthetic treatments. By combining French aesthetic philosophy with strict quality standards, AxeniQ provides practitioners with a trusted solution for achieving smooth and natural-looking results.
Composition:
Each vial of AxeniQ contains a vacuum-dried powder in a single-dose format. Its composition includes 100 units of Clostridium botulinum toxin type A, 0.5 mg of Human Serum Albumin, and 0.9 mg of Sodium Chloride. Prior to use, it should be diluted with preservative-free sterile 0.9% saline to achieve a final concentration of 100 U/2.5 mL (4 U/0.1 mL).
Mechanism of Action and Performance:
AxeniQ delivers precise and predictable performance due to its high purity and verified molecular structure. SDS-PAGE analysis confirms the correct molecular weight profile of the botulinum toxin complex, supporting its structural integrity, stability, and consistent quality. Its controlled diffusion profile enables targeted action, contributing to accurate and refined aesthetic outcomes.
Advantages and Key Features:
Key advantages of AxeniQ include its high purity, stable and predictable clinical results, and strict quality control in manufacturing. The product is designed with a precise diffusion profile, allowing for smooth and natural-looking aesthetic results. Its advanced production standards, combined with French aesthetic expertise, make it a reliable choice for practitioners seeking precision in aesthetic treatments.
Final Outcome for the Consumer:
AxeniQ enables the achievement of smooth, natural, and balanced facial aesthetic results. With its consistent performance and reliable outcomes, it enhances patient satisfaction and supports a professional and confident treatment experience.
